Молекулярный мониторинг у пациентов с хроническим миелолейкозом: корреляция с цитогенетическим ответом, прогностическое значение, оценка ответа на терапию

SUMMARY Modern treatment options for the chronic myelogenous leukemia require the regular performance of molecular monitoring of the BCR / ABL expression level by means of the Real Time PCR. Achievement of the major molecular response (MMR) is considered to be a prominent hallmark of the successful therapy with the inhibitors of tyrosine kinase activity and a very important prognostic factor. Our aim was to report the data of molecular monitoring of BCR / ABL gene expression in CML patients treated with imatinib during the 5 years experience of this work in the real clinical conditions of the Research Center for Hematology (Moscow, Russia). The strict correlation between cytogenetic and molecular data was shown and unevenness of CML patients in complete cytogenetic response (CCR) when they were analyzed in the terms of molecular response. We found it out that 1 % IS was a threshold that shouldn't be exceeded to keep cytogenetic response for a long time of observation. The level of BCR / ABL expression at the start of imatinib treatment had a great prognostic significance. All changes in cytogenetic and molecular data showed the same trend and their dynamics adequately reflected evolution of disease.